aTyr Pharma CFO receives 410K-share stock option award

The option vests in 48 equal monthly installments beginning November 1, 2026, and will be fully exercisable on November 1, 2030.

Rhea-AI Filing Summary

aTyr Pharma Chief Financial Officer Brandon Yaras received an employee stock option award covering 410,000 shares of common stock on October 1, 2026. The option has an exercise price of $0.30 per share and expires October 1, 2036. It vests in 48 equal monthly installments beginning November 1, 2026, and will be fully exercisable on November 1, 2030. The option is subject to accelerated vesting upon termination without cause upon a change of control of the issuer.

Insider Trade Summary

Grant/Award: 410,000 shares

Grant/Award 1 txn

Insider Yaras Brandon

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy) F1	410,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 410,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning November 1, 2026, such that this option will be fully exercisable on November 1, 2030. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.

Key Figures

Shares subject to option: 410,000 shares Exercise price: $0.30 per share Vesting installments: 48 equal monthly installments +2 more

5 metrics

Shares subject to option 410,000 shares Option award dated October 1, 2026

Exercise price $0.30 per share Option award dated October 1, 2026

Vesting installments 48 equal monthly installments Beginning November 1, 2026

Fully exercisable date November 1, 2030 Option award

Expiration date October 1, 2036 Option award

Key Terms

Employee Stock Option (right to buy), vesting, accelerated vesting

3 terms

Employee Stock Option (right to buy) financial

"The shares subject to this option"

vesting financial

"shall vest and become exercisable in 48 equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

accelerated vesting financial

"subject to accelerated vesting upon termination without cause"

A contract feature that makes stock awards, options, or restricted shares become owned or exercisable earlier than the original schedule. It shortens or cancels the waiting period so recipients can sell, transfer, or exercise their equity sooner — think of a timed lock that is unlocked ahead of schedule. It matters to investors because it changes when shares enter the market, who controls them, and how much dilution or ownership concentration happens.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did ATYR CFO Brandon Yaras receive?

Brandon Yaras received an employee stock option covering 410,000 shares of common stock on October 1, 2026. The option has an exercise price of $0.30 per share.

What is the vesting schedule for Brandon Yaras's ATYR option?

The option vests in 48 equal monthly installments beginning November 1, 2026, and will be fully exercisable on November 1, 2030. It expires October 1, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 04:04 PM Accepted by SEC EDGAR 10/01/2026 - 04:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yaras Brandon

(Last) (First) (Middle)

10240 SORRENTO VALLEY ROAD

SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
aTYR PHARMA INC [ ATYR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$0.3	10/01/2026		A		410,000		(1)	10/01/2036	Common Stock	410,000	$0	410,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning November 1, 2026, such that this option will be fully exercisable on November 1, 2030. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.

	/s/ Brandon Yaras	10/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)